scholarly journals The Value of 18F-PSMA-1007 PET/CT in Identifying High-Risk Prostate Cancer

2020 ◽  
Author(s):  
Jun-jie Hong ◽  
Bo-le Liu ◽  
Zhi-qiang Wang ◽  
Kun Tang ◽  
Xiao-wei Ji ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostate Tumor ◽  
Roc Curve Analysis ◽  
High Risk Prostate Cancer ◽  
Standardized Uptake Values ◽  
Pet Ct ◽  
Primary Prostate Tumor

Abstract Background: Clinical management decisions on prostate cancer (PCa) are often based on a determination of risk. 68Ga-prostate-specific membrane antigen (PSMA)-11-positron-emission-tomography (PET)/ computer-tomography (CT) is an attractive modality to assess biochemical recurrence of PCa, detect metastatic disease and stage of primary PCa, making it a promising strategy for risk stratification. However, due to some limitation of 68Ga-PSMA-11 the development of alternative tracers is of high interest. In this study, we aimed to investigate the value of the new PET trace 18F-PSMA-1007 in identifying high-risk PCa.Methods: 170 patients with primary PCa underwent 18F-PSMA-1007 PET/CT were retrospectively analyzed. According to the European Association of Urology (EAU) guidelines on prostate cancer for PCa, patients were classified into low-intermediate-risk (LMR) group or high-risk (HR) group. The maximum standardized uptake values (SUVmax) of the primary prostate tumor was measured on PET/CT images. The diagnostic performance of PET/CT for LMR and HR PCa were calculated and the relationship between the SUVmax of primary prostate tumor, prostate-specific antigen (PSA) level and Gleason score (GS) were analyzed.Results: Of all 170 patients, 55 patients were classified into LMR group and 115 patients were classified into HR group. There was a significant positive correlation between the PSA level/GS and SUVmax (r = 0.597, r = 0.446, P < 0.001, respectively). Tumors with GS of 6 and 7a showed significantly lower 18F-PSMA-1007 uptake compared to patients with GS of 8, 9, and 10 (P < 0.001). SUVmax in patients of HR was significantly higher than those of LMR (median SUVmax: 20.20 versus 8.40; P < 0.001). In receiver operating characteristic (ROC) curve analysis, the optimal cutoff value of the SUVmax for identifying high-risk PCa was set as 10.78 (area under the curve [AUC]: 0.873; sensitivity: 90.4%; specificity: 69.1%). Conclusion: 18F-PSMA-1007 PET/CT showed the powerful diagnosis efficacy for high-risk PCa, which can be used as an objective imaging reference index for clinical reference.

scholarly journals The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jun-jie Hong ◽  
Bo-le Liu ◽  
Zhi-qiang Wang ◽  
Kun Tang ◽  
Xiao-wei Ji ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostate Tumor ◽  
High Risk Prostate Cancer ◽  
Standardized Uptake Values ◽  
Pet Ct ◽  
Primary Prostate Tumor

Abstract Background Clinical management decisions on prostate cancer (PCa) are often based on a determination of risk. 68Ga-prostate-specific membrane antigen (PSMA)-11-positron emission tomography (PET)/computer tomography (CT) is an attractive modality to assess biochemical recurrence of PCa, detect metastatic disease and stage of primary PCa, making it a promising strategy for risk stratification. However, due to some limitation of 68Ga-PSMA-11 the development of alternative tracers is of high interest. In this study, we aimed to investigate the value of 18F-PSMA-1007 in identifying non-metastatic high-risk PCa. Methods A total of 101 patients with primary non-metastatic PCa who underwent 18F-PSMA-1007 PET/CT were retrospectively analyzed. According to the European Association of Urology guidelines on PCa, patients were classified into intermediate-risk (IR) group or high-risk (HR) group. The maximum standardized uptake values (SUVmax) of the primary prostate tumor were measured on PET/CT images. The diagnostic performance of PET/CT for IR and HR PCa was calculated, and the relationship between the SUVmax of primary prostate tumor, prostate-specific antigen (PSA) level and Gleason score (GS) was analyzed. Results Of all 101 patients, 49 patients were classified into IR group and 52 patients were classified into HR group. There was a significant positive correlation between PSA level/GS and SUVmax (r = 0.561, r = 0.496, P < 0.001, respectively). Tumors with GS 6 and 7a showed significantly lower 18F-PSMA-1007 uptake compared to patients with GS 8 and 9 (P < 0.01). SUVmax in patients of HR was significantly higher than those of IR (median SUVmax: 16.85 vs 7.80; P < 0.001). In receiver operating characteristic curve analysis, the optimal cutoff value of the SUVmax for identifying high-risk PCa was set as 9.05 (area under the curve: 0.829; sensitivity: 90.4%; specificity: 65.3%). Conclusion 18F-PSMA-1007 PET/CT showed the powerful diagnosis efficacy for high-risk PCa, which can be used as an objective imaging reference index for clinical reference.

scholarly journals MP67-04 PREOPERATIVE 18F-FLUCICLOVINE PET/CT FINDINGS MAY BE PREDICTIVE OF POST-OPERATIVE PROSTATE-SPECIFIC ANTIGEN (PSA) IN PATIENTS WITH HIGH RISK PROSTATE CANCER

2020 ◽  
Vol 203 ◽  
pp. e1026
Author(s):  
Akinyemi Akintayo* ◽  
Olayinka Abiodun-Ojo ◽  
Mehrdad Alemozaffar ◽  
Oladunni Akin-Akintayo ◽  
Dattatraya Patil ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
High Risk Prostate Cancer ◽  
Ct Findings ◽  
Pet Ct ◽  
Risk Prostate Cancer

scholarly journals Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer

2016 ◽  
Vol 10 (4) ◽  
pp. 217-220 ◽  
Author(s):  
Adama Ouattara ◽  
Tiago Ribeiro de Oliveira ◽  
Serge Holz ◽  
Hannes Van den Bossche ◽  
David Strybol ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Thyroid Carcinoma ◽  
Specific Antigen ◽  
Needle Aspiration ◽  
Adjuvant Radiation ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma. To our knowledge, this is the first report of a thyroid cancer diagnosed with 11C-choline PET/CT for prostate cancer staging.

11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer

2016 ◽  
Vol 36 (12) ◽  
pp. 6475-6480 ◽  
Author(s):  
SARA STRANDBERG ◽  
CAMILLA THELLENBERG KARLSSON ◽  
MATTIAS OGREN ◽  
JAN AXELSSON ◽  
KATRINE RIKLUND
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Bone Scintigraphy ◽  
Primary Staging ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

18F-F-Choline PET/CT in staging of newly diagnosed high-risk prostate cancer

2021 ◽  
Vol 45 (4) ◽  
pp. 223
Author(s):  
Y. Benameur ◽  
O. Ait Sahel ◽  
S. Nabih Oueriagli ◽  
J. El Bekkali ◽  
A. Doudouh
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Newly Diagnosed ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

scholarly journals Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study

2018 ◽  
Vol 44 (5) ◽  
pp. 892-899 ◽  
Author(s):  
Aline B. Mattiolli ◽  
Allan Santos ◽  
Andreia Vicente ◽  
Marcelo Queiroz ◽  
Diogo Bastos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Multicenter Study ◽  
High Risk Prostate Cancer ◽  
Psma Pet ◽  
Pet Ct ◽  
Risk Prostate Cancer

Detection of Lymph Node Metastases in Patients With Prostate Cancer: Comparing Conventional and Digital [18F]-fluorocholine PET-CT Using Histopathology as Reference

2021 ◽  
Author(s):  
Mimmi Bjöersdorff ◽  
Christopher Puterman ◽  
Jenny Oddstig ◽  
Jennifer Amidi ◽  
Sophia Zackrisson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Lymph Nodes ◽  
Lymph Node Metastases ◽  
Reconstruction Algorithms ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer ◽  
Node Metastases

Abstract Background: Positron emission tomography-computed tomography (PET-CT) can be used to detect and stage metastatic lymph nodes in intermediate to high-risk prostate cancer. Improvements to hardware, such as digital technology, and to software, such as reconstruction algorithms, have recently been made. We compared the capability of detecting regional lymph node metastases using conventional and digital silicon photomultiplier (SiPM)-based PET-CT technology for [18F]-fluorocholine (FCH). Extended pelvic lymph node dissection (ePLND) histopathology was used as the reference method.Methods: Retrospectively, a consecutive series of patients with prostate cancer who had undergone staging with FCH PET-CT before ePLND were included. Images were obtained with either a conventional or a SiPM-based PET-CT and compared. FCH uptake in pelvic lymph nodes beyond the uptake in the mediastinal blood pool was considered to be abnormal.Results: One hundred eighty patients with intermediate or high-risk prostate cancer were examined using a conventional Philips Gemini PET-CT (n = 93) between 2015 and 2017 or a digital GE Discovery MI PET-CT (n = 87) from 2017 to 2018. Images that were obtained using the Philips Gemini PET-CT system showed 19 patients (20%) with suspected lymph node metastases compared with 40 patients (46%) using the GE Discovery MI PET-CT. Sensitivity, specificity, and positive and negative predictive value (PPV and NPV) were 0.30, 0.84, 0.47, and 0.72, respectively, for the Philips Gemini and 0.60, 0.58, 0.30, and 0.83, respectively for GE Discovery MI. Area under the curve (AUC) in a receiver operating characteristics (ROC) analysis was similar between the two PET-CT systems (0.58 and 0.58, P = 0.8).Conclusions: A marked difference in sensitivity and specificity was found for the different PET-CT systems, although similar overall diagnostic performance. This is probably due to differences in both hard- and software, including reconstruction algorithms, and should be considered when new technology is introduced.

scholarly journals Circulating mRNA signature as a marker for high-risk prostate cancer

2019 ◽  
Vol 41 (2) ◽  
pp. 139-145
Author(s):  
Marilesia Ferreira De Souza ◽  
Hellen Kuasne ◽  
Mateus De Camargo Barros-Filho ◽  
Heloísa Lizotti Cilião ◽  
Fabio Albuquerque Marchi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Specific Antigen ◽  
Treatment Decision ◽  
Tumor Stage ◽  
Aggressive Disease ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Invasive Method ◽  
Biopsy Gleason Score

Abstract Prostate cancer (PCa) is the second most common cancer in men. The indolent course of the disease makes the treatment choice a challenge for physicians and patients. In this study, a minimally invasive method was used to evaluate the potential of molecular markers in identifying patients with aggressive disease. Cell-free plasma samples from 60 PCa patients collected before radical prostatectomy were used to evaluate the levels of expression of eight genes (AMACR, BCL2, NKX3-1, GOLM1, OR51E2, PCA3, SIM2 and TRPM8) by quantitative real-time PCR. Overexpression of AMACR, GOLM1, TRPM8 and NKX3-1 genes was significantly associated with aggressive disease characteristics, including extracapsular extension, tumor stage and vesicular seminal invasion. A trio of genes (GOLM1, NKX3-1 and TRPM8) was able to identify high-risk PCa cases (85% of sensitivity and 58% of specificity), yielding a better overall performance compared with the biopsy Gleason score and prostate-specific antigen, routinely used in the clinical practice. Although more studies are required, these circulating markers have the potential to be used as an additional test to improve the diagnosis and treatment decision of high-risk PCa patients.

Sign in / Sign up

Export Citation Format

Share Document